The document is an intimation of a scheduled Analyst/Institutional Investor meeting, filed as a regulatory disclosure.
The event is a series of One-on-One Meetings scheduled for June 22, 2026.
The meeting is with SiMPL PMS arranged by Kotak Securities.
The stated purpose of the event is for investor interaction and outreach.
The disclosure is made pursuant to Regulation 30 read with Part A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The company has indicated that no unpublished price sensitive information (UPSI) will be shared during the meeting. This is implied by the standard nature of the compliance intimation and the absence of any financial data or guidance in the announcement.
The schedule of meetings is subject to change due to exigencies on the part of the Investor, Analyst, or the Company.
Additional Notes Section
The disclosure is signed by Pallerlamudi Sampath Kumar, the Company Secretary & Compliance Officer of Gland Pharma Limited.
No financial data, presentation decks, transcripts, or recordings were mentioned as being part of this announcement or to be made available.
No attachments, such as invites or compliance letters, were mentioned as being included with this filing.
